July 5, 2024
The U.S. Food and Drug Administration today revised the emergency use authorization (EUA) for bamlanivimab and etesevimab, administered together, to include emergency use as post-exposure prophylaxis (prevention) […]
July 5, 2024
Spanish version Update [6/29/2020] FDA is alerting consumers of Saniderm Products and UVT Inc.’s voluntary recall of Saniderm Advanced Hand Sanitizer. Following FDA’s recommendation, two distributors – […]
July 5, 2024
TOPLINE: A panel has issued an opinion on managing actinic keratosis (AK) in immunocompromised (IM) patients, given that immunosuppression increases the risk for these lesions and […]
July 5, 2024
FDA authorized Paxlovid (nirmatrelvir and ritonavir) in December 2021 for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older […]
July 5, 2024
The following home preparation instructions for doxycycline, prepared by the CDC, are not to be used except in the case of a declared public health emergency. […]
July 5, 2024
Akeega (niraparib and abiraterone acetate) Zejula (niraparib) Haemorrhage FDA is evaluating the need for regulatory action. Certain amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate and dextroamphetamine sulfate […]
July 5, 2024
Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at a high risk for infection, according to an interim […]
July 5, 2024
TOPLINE: High-dose antipsychotics, particularly quetiapine, clozapine, and olanzapine, are linked to increased pneumonia risk in patients with schizophrenia, new data showed. Monotherapy with high anticholinergic burden […]
July 5, 2024
TOPLINE: GPT-4 generated highly accurate pancreatic cancer synoptic reports from original reports, outperforming GPT-3.5. Using GPT-4 reports instead of original reports, surgeons were able to better […]